Stockreport

Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease

Voyager Therapeutics, Inc.  (VYGR) 
Last voyager therapeutics, inc. earnings: 3/3 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.voyagertherapeutics.com
PDF - Late-breaking oral presentation: IV delivery of VY1706, a CNS penetrant AAV gene therapy for AD, demonstrates compelling pharmacology and safety in a 3-month GLP toxic [Read more]